NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-23
Reading SEM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on maintaining revenue and earnings guidance. The current thesis state is stable, supported by strong recent financial performance despite some volatility in management execution.
The market currently prices SEM as cheap compared to its peers, with an expectations gap indicating that some positive developments may not be fully reflected in the stock. The low fragility tier suggests that there are no immediate concerns that could disrupt this valuation.
Management is on track to meet revenue guidance for 2026, although there is mixed progress on earnings per share and adjusted EBITDA targets. The near-term risk is notable, as there is a 40% chance of missing estimates, which could impact future performance.
The thesis hinges on the ability of SEM to maintain its guidance and the performance of sector bellwethers like HCA, THC, and DVA. If these companies continue to perform well, it could provide a tailwind for SEM, while any negative shifts in their performance could pose risks.
Overall, SEM's fundamentals and sector dynamics suggest a stable outlook for the next 1 to 3 years. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company is set to be acquired, which supports growth. However, it recently missed earnings expectations, which weakens the outlook.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Confirming EPS guidance shows strong earnings. This helps build investor confidence.
Confirms:Q2 EPS reported between $1.22 and $1.32.
Disproves:Q2 EPS falls below $1.22.
Why it matters: The merger affects control and operations of Select Medical. It is a major change.
Confirms:The merger is done. Select Medical is now a fully-owned part of the company.
Disproves:The merger might be delayed or fail. This could happen because of rules or other issues.
Why it matters: The merger will take Select Medical private and affect stockholder value. It is crucial for future operations.
Confirms one read:The merger gets all needed approvals from regulators and stockholders by mid-2026.
Confirms the other:The merger fails to secure necessary approvals or is delayed beyond mid-2026.
Why it matters: The merger changes ownership. It may affect future operations. Investors want to see if it leads to better management.
Confirms:The merger is done. Select Medical is now off the NYSE.
Disproves:The merger fails to close or faces significant delays beyond July 1, 2026.
Why it matters: Changes in sector growth can affect Select Medical's performance. This can change their outlook.
Confirms:Sector revenue growth drops below 10% year over year.
Disproves:Sector revenue growth remains above 10% year over year.
Why it matters: Changes in EPS guidance may show shifts in how much money the company makes.
Confirms one read:Management maintains EPS guidance of $1.22 to $1.32 for 2026.
Confirms the other:Management lowers EPS guidance to below $1.22 for 2026.
Why it matters: The earnings report will show how well the company is doing. Strong results could boost investor confidence.
Confirms:Earnings per share (EPS) beats analyst expectations by more than 10%.
Disproves:EPS falls short of analyst expectations by more than 10%.
Why it matters: This range shows how well the company operates and makes money. These are key for long-term growth.
Confirms:Adjusted EBITDA for 2026 remains within the range of $520 million to $540 million.
Disproves:Adjusted EBITDA guidance is now below $520 million for 2026.
Why it matters: Regulatory problems could slow down the merger. They may also impact future operations.
Confirms:No regulatory problems come up that delay the merger or need more approvals.
Disproves:Regulatory groups raise issues or need more approvals, which delays the merger.
Why it matters: This growth rate aligns with management's guidance for 2026. It indicates ongoing business strength.
Confirms:Q2 revenue growth is 5.6% or greater compared to Q2 2025.
Disproves:Q2 revenue growth falls below 5.0% YoY.
Why it matters: Changes in dividend payments can show how healthy a company is. They also show management's confidence in future earnings.
Confirms one read:The board declares a dividend increase or maintains the current dividend of $0.0625 per share.
Confirms the other:The board cuts or suspends the dividend payment.
Why it matters: Management thinks adjusted EBITDA for 2026 will be $520 million to $540 million. This shows stability after the merger.
Confirms:Adjusted EBITDA for Q2 meets or exceeds the guidance range.
Disproves:Adjusted EBITDA falls below $520 million for Q2.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
